14.35 0.00 (0.00%)
After hours: 4:47PM EDT
|Bid||14.39 x 100|
|Ask||14.83 x 100|
|Day's range||13.84 - 14.74|
|52-week range||8.36 - 27.09|
|PE ratio (TTM)||N/A|
|Earnings date||8 May 2018 - 14 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.20|
Omeros Corporation announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018.
Omeros Corporation today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery Congress in Washington, D.C., April 13-17, 2018.
Omeros Corporation today announced that the Veterans Administration has added OMIDRIA® to the VA National Formulary.
In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.
Omeros Corporation today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP, a healthcare-focused investment firm.
Omeros (OMER) generated total revenue of $64.8 million in fiscal 2017, compared with $41.6 million in fiscal 2016. Between fiscal 2016 and fiscal 2017, Omeros’s product sale costs fell to $1 million from $1.4 million, and its SG&A (selling, general and administrative expenses) rose to $52 million from $43.7 million.
Omeros Corp. shares surged 45% in extremely heavy morning trade Thursday on a new government spending bill that benefits its cataract surgery drug Omidria. Omidria's "pass-through" status with ...
On a per-share basis, the Seattle-based company said it had a loss of 34 cents. Losses, adjusted for non-recurring costs, came to 25 cents per share. The drug developer posted revenue of $13.8 million ...
Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for
Omeros Corporation today announced that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017, on Thursday, March 1, 2018, after the market closes.
Omeros Corporation today announced new results from the company’s ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy .
Omeros Corp. is the latest short target for FourWorld Capital Management LLC, as the investment adviser issues a new report on the drugmaker with a price target of $4.00, suggesting a more than 70 percent ...
Omeros Corporation announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products issued a positive opinion on Omeros’ application for orphan drug designation of OMS721 in the treatment of primary Immunoglobulin A nephropathy . OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 , the effector enzyme of the lectin ...
Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Omeros’ application for orphan drug designation of OMS721 in the treatment of primary Immunoglobulin A nephropathy (IgAN). OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system, and is in Phase 3 development for each of IgAN, atypical hemolytic uremic syndrome (aHUS), and hematopoietic stem cell transplant-associated thrombotic microangiopathy (TMA).
Omeros shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 85.
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.